Skip to main content
. 2022 Mar 29;14(7):1736. doi: 10.3390/cancers14071736

Table 1.

Correlations of PD-L1 and CD8 status with clinicopathological parameters.

Factors n CD8all
High
CD8all
Low
p-Value CD8int
High
CD8int
Low
p-Value n CPS ≥ 1 CPS < 1 p-Value
pT 0.033 0.001 0.015
T1 45
(11%)
20 (44.4%) 25 (55.5%) 29 (64.4%) 16 (35.6%) 48 (11.7%) 16 (33.3%) 32 (66.7%)
T2 54
(13.3%)
36 (66.7%) 18 (33.3%) 37 (68.5%) 17 (31.5%) 55 (13.5%) 28 (50.9%) 27 (49.1%)
T3 146 (35.9%) 80 (54.8%) 66 (45.2%) 87 (59.6%) 59 (40.4%) 144 (35.3%) 54 (37.5%) 90 (62.5%)
T4 162 (39.8%) 71 (43.8%) 91 (56.2%) 65 (40.1%) 97 (59.9%) 161 (39.5%) 44 (27.3%) 117 (72.7%)
pN 0.37 0.045 0.112
N0 112 (27.5%) 61 (54.5%) 51 (45.5%) 69 (61.6%) 43 (38.4%) 112 (27.8%) 46 (41.1%) 66 (58.9%)
N1-3 295 (72.5%) 146 (49.5%) 149 (50.5%) 149 (50.5%) 146 (49.5%) 291 (72.2%) 95 (32.6%) 196 (67.4%)
Grading 0.278 0.107 0.041
G1 21
(5.2%)
8
(38.1%)
13 (61.9%) 14 (66.6%) 7
(33.3%)
23
(5.6%)
8
(34.8%)
15 (65.2%)
G2 96 (23.6%) 45 (46.9%) 51 (53.1%) 58 (60.4%) 38 (39.6%) 97 (23.8%) 44 (45.4%) 53 (54.6%)
G3 290 (71.2%) 154 (53.1%) 136 (46.9%) 146 (50.3%) 144 (49.7%) 288 (70.6%) 90 (31.3%) 198 (68.7%)
Laurén 0.933 0.022 <0.001
Intestinal 207 (50.9%) 102 (49.3%) 105 (50.7%) 125 (60.4%) 82 (39.6%) 211 (51.7%) 101 (47.9%) 110 (52.1%)
Diffuse 131 (32.2%) 69 (52.7%) 62 (47.3%) 58 (44.3%) 73 (55.7%) 127 (31.1%) 22 (17.3%) 105 (82.7%)
Mixed 65
(16%)
34 (52.3%) 31 (47.7%) 32 (49.2%) 33 (50.8%) 66 (16.2%) 16 (24.2%) 50 (75.8%)
Indeterm. 4
(0.9%)
2
(50%)
2
(50%)
3
(75%)
1
(25%)
4
(1%)
3
(75%)
1
(25%)